Beta Thalassemia Testing Comprehensive Study by Application (Hospitals, Biotechnological Laboratories, Diagnostic Laboratories, Educational Research Institutes, Pharmaceutical Industries), Technology (Perinatal Testing {Complete Blood Count and DNA Testing}, Prenatal Testing {Prenatal Genetic Testing and Chronic Villus Testing}, Preimplantation Genetic Diagnosis) Players and Region - Global Market Outlook to 2027

Beta Thalassemia Testing Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Beta Thalassemia Testing Market?

Beta thalassemia is a blood disorder in which the production of hemoglobin is reduced. Hemoglobin is the iron-containing protein in the red blood cells (RBCs) that carries oxygen to cells throughout the body. Thus people with beta thalassemia have low levels of hemoglobin which leads to a shortage of oxygen in many parts of the body. Pale skin, weakness, fatigue are the complications occur due to beta thalassemia. The people affecting with beta-thalassemia also have a risk of developing blood clots. Beta thalassemia testing includes Complete Blood Count (CBC), DNA testing, parental genetic testing, Chorionic Villus Sampling (CVS) and Preimplantation Genetic Diagnosis (PGD).

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledGenorama Ltd. (Estonia), HiMedia Laboratories (India), DiagCor Bioscience Inc Ltd (China), Tosoh Bioscience, Inc. (United States), Goffin Molecular Technologies B.V. (Netherlands), Devyser (Sweden), Hybribio (China), Bio-Active Co., Ltd. (Thailand), Bio-Rad Laboratories (United States) and Genomed Biotech (United Kingdom)


The market study is being classified, by Application (Hospitals, Biotechnological Laboratories, Diagnostic Laboratories, Educational Research Institutes and Pharmaceutical Industries) and major geographies with country level break-up. According to AMA, the Global Beta Thalassemia Testing market is expected to see steady growth rate.

Genorama Ltd. (Estonia), HiMedia Laboratories (India), DiagCor Bioscience Inc Ltd (China), Tosoh Bioscience, Inc. (United States), Goffin Molecular Technologies B.V. (Netherlands), Devyser (Sweden), Hybribio (China), Bio-Active Co., Ltd. (Thailand), Bio-Rad Laboratories (United States) and Genomed Biotech (United Kingdom) are some of the key players profiled in the study.

Global Beta Thalassemia Testing is a fragmented market due to the presence of various players. The companies are planning strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Research Analyst at AMA predicts that United States and Chinese Players will contribute to the maximum growth of Global Beta Thalassemia Testing market throughout the forecasted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Beta Thalassemia Testing market by Type, Application and Region.

On the basis of geography, the market of Beta Thalassemia Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Growing Number of Patients Suffering From Beta Thalassemia
  • Development of Various Rapid Diagnostic Methods

Market Trend
  • Use of Preimplantation Genetic Diagnosis (PGD)

Restraints
  • High Implementation Cost of Sophisticated Clinical and Preclinical Imaging Systems

Opportunities
  • Increasing Prevalence of Thalassemia

Challenges
  • Lack of Awareness about the Disorder


Market Leaders and some development strategies
On 14th October 2021, Tosoh Bioscience, Inc. acquired Semba Biosciences. With this acquisition, Tosoh will able to offer unparalleled efficiency and productivity in downstream processes and significantly decrease the cost of manufacturing.
In 2019, Bristol-Myers Squibb Company acquired Celgene Corporation. The transaction includes further progress relating to the patent estate for REVLIMID, the U.S. Food and Drug Administration (FDA) approval of INREBIC (fedratinib) for the treatment of certain forms of myelofibrosis, the U.S. FDA approval of REBLOZYL (luspatercept-aamt) for the treatment of anemia in certain adult patients with beta thalassemia, and regulatory filings of luspatercept and ozanimod in the U.S. and Europe.
As per the Standards of Care Guideline, All patients should undergo at least an annual comprehensive assessment at a thalassemia center. During such an assessment, recommendations are summarized after consultation with multiple specialists and communicated directly to the primary provider and family.

Key Target Audience
Technology Investors, Research Professionals, Research Institutes, Government Body & Associations and End-user

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Biotechnological Laboratories
  • Diagnostic Laboratories
  • Educational Research Institutes
  • Pharmaceutical Industries
By Technology
  • Perinatal Testing {Complete Blood Count and DNA Testing}
  • Prenatal Testing {Prenatal Genetic Testing and Chronic Villus Testing}
  • Preimplantation Genetic Diagnosis

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Number of Patients Suffering From Beta Thalassemia
      • 3.2.2. Development of Various Rapid Diagnostic Methods
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness about the Disorder
    • 3.4. Market Trends
      • 3.4.1. Use of Preimplantation Genetic Diagnosis (PGD)
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Beta Thalassemia Testing, by Application, Technology and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Beta Thalassemia Testing (Value)
      • 5.2.1. Global Beta Thalassemia Testing by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Biotechnological Laboratories
        • 5.2.1.3. Diagnostic Laboratories
        • 5.2.1.4. Educational Research Institutes
        • 5.2.1.5. Pharmaceutical Industries
      • 5.2.2. Global Beta Thalassemia Testing by: Technology (Value)
        • 5.2.2.1. Perinatal Testing {Complete Blood Count and DNA Testing}
        • 5.2.2.2. Prenatal Testing {Prenatal Genetic Testing and Chronic Villus Testing}
        • 5.2.2.3. Preimplantation Genetic Diagnosis
      • 5.2.3. Global Beta Thalassemia Testing Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Beta Thalassemia Testing (Volume)
      • 5.3.1. Global Beta Thalassemia Testing by: Application (Volume)
        • 5.3.1.1. Hospitals
        • 5.3.1.2. Biotechnological Laboratories
        • 5.3.1.3. Diagnostic Laboratories
        • 5.3.1.4. Educational Research Institutes
        • 5.3.1.5. Pharmaceutical Industries
      • 5.3.2. Global Beta Thalassemia Testing by: Technology (Volume)
        • 5.3.2.1. Perinatal Testing {Complete Blood Count and DNA Testing}
        • 5.3.2.2. Prenatal Testing {Prenatal Genetic Testing and Chronic Villus Testing}
        • 5.3.2.3. Preimplantation Genetic Diagnosis
      • 5.3.3. Global Beta Thalassemia Testing Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Beta Thalassemia Testing (Price)
  • 6. Beta Thalassemia Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Genorama Ltd. (Estonia)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. HiMedia Laboratories (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. DiagCor Bioscience Inc Ltd (China)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Tosoh Bioscience, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Goffin Molecular Technologies B.V. (Netherlands)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Devyser (Sweden)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Hybribio (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bio-Active Co., Ltd. (Thailand)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bio-Rad Laboratories (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Genomed Biotech (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Beta Thalassemia Testing Sale, by Application, Technology and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Beta Thalassemia Testing (Value)
      • 7.2.1. Global Beta Thalassemia Testing by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Biotechnological Laboratories
        • 7.2.1.3. Diagnostic Laboratories
        • 7.2.1.4. Educational Research Institutes
        • 7.2.1.5. Pharmaceutical Industries
      • 7.2.2. Global Beta Thalassemia Testing by: Technology (Value)
        • 7.2.2.1. Perinatal Testing {Complete Blood Count and DNA Testing}
        • 7.2.2.2. Prenatal Testing {Prenatal Genetic Testing and Chronic Villus Testing}
        • 7.2.2.3. Preimplantation Genetic Diagnosis
      • 7.2.3. Global Beta Thalassemia Testing Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Beta Thalassemia Testing (Volume)
      • 7.3.1. Global Beta Thalassemia Testing by: Application (Volume)
        • 7.3.1.1. Hospitals
        • 7.3.1.2. Biotechnological Laboratories
        • 7.3.1.3. Diagnostic Laboratories
        • 7.3.1.4. Educational Research Institutes
        • 7.3.1.5. Pharmaceutical Industries
      • 7.3.2. Global Beta Thalassemia Testing by: Technology (Volume)
        • 7.3.2.1. Perinatal Testing {Complete Blood Count and DNA Testing}
        • 7.3.2.2. Prenatal Testing {Prenatal Genetic Testing and Chronic Villus Testing}
        • 7.3.2.3. Preimplantation Genetic Diagnosis
      • 7.3.3. Global Beta Thalassemia Testing Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Beta Thalassemia Testing (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Beta Thalassemia Testing: by Application(USD Million)
  • Table 2. Beta Thalassemia Testing Hospitals , by Region USD Million (2016-2021)
  • Table 3. Beta Thalassemia Testing Biotechnological Laboratories , by Region USD Million (2016-2021)
  • Table 4. Beta Thalassemia Testing Diagnostic Laboratories , by Region USD Million (2016-2021)
  • Table 5. Beta Thalassemia Testing Educational Research Institutes , by Region USD Million (2016-2021)
  • Table 6. Beta Thalassemia Testing Pharmaceutical Industries , by Region USD Million (2016-2021)
  • Table 7. Beta Thalassemia Testing: by Technology(USD Million)
  • Table 8. Beta Thalassemia Testing Perinatal Testing {Complete Blood Count and DNA Testing} , by Region USD Million (2016-2021)
  • Table 9. Beta Thalassemia Testing Prenatal Testing {Prenatal Genetic Testing and Chronic Villus Testing} , by Region USD Million (2016-2021)
  • Table 10. Beta Thalassemia Testing Preimplantation Genetic Diagnosis , by Region USD Million (2016-2021)
  • Table 11. South America Beta Thalassemia Testing, by Country USD Million (2016-2021)
  • Table 12. South America Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 13. South America Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 14. Brazil Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 15. Brazil Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 16. Argentina Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 17. Argentina Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 18. Rest of South America Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 19. Rest of South America Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 20. Asia Pacific Beta Thalassemia Testing, by Country USD Million (2016-2021)
  • Table 21. Asia Pacific Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 22. Asia Pacific Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 23. China Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 24. China Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 25. Japan Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 26. Japan Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 27. India Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 28. India Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 29. South Korea Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 30. South Korea Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 31. Taiwan Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 32. Taiwan Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 33. Australia Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 34. Australia Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 35. Rest of Asia-Pacific Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 36. Rest of Asia-Pacific Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 37. Europe Beta Thalassemia Testing, by Country USD Million (2016-2021)
  • Table 38. Europe Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 39. Europe Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 40. Germany Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 41. Germany Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 42. France Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 43. France Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 44. Italy Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 45. Italy Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 46. United Kingdom Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 47. United Kingdom Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 48. Netherlands Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 49. Netherlands Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 50. Rest of Europe Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 51. Rest of Europe Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 52. MEA Beta Thalassemia Testing, by Country USD Million (2016-2021)
  • Table 53. MEA Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 54. MEA Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 55. Middle East Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 56. Middle East Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 57. Africa Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 58. Africa Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 59. North America Beta Thalassemia Testing, by Country USD Million (2016-2021)
  • Table 60. North America Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 61. North America Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 62. United States Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 63. United States Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 64. Canada Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 65. Canada Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 66. Mexico Beta Thalassemia Testing, by Application USD Million (2016-2021)
  • Table 67. Mexico Beta Thalassemia Testing, by Technology USD Million (2016-2021)
  • Table 68. Beta Thalassemia Testing Sales: by Application(Units)
  • Table 69. Beta Thalassemia Testing Sales Hospitals , by Region Units (2016-2021)
  • Table 70. Beta Thalassemia Testing Sales Biotechnological Laboratories , by Region Units (2016-2021)
  • Table 71. Beta Thalassemia Testing Sales Diagnostic Laboratories , by Region Units (2016-2021)
  • Table 72. Beta Thalassemia Testing Sales Educational Research Institutes , by Region Units (2016-2021)
  • Table 73. Beta Thalassemia Testing Sales Pharmaceutical Industries , by Region Units (2016-2021)
  • Table 74. Beta Thalassemia Testing Sales: by Technology(Units)
  • Table 75. Beta Thalassemia Testing Sales Perinatal Testing {Complete Blood Count and DNA Testing} , by Region Units (2016-2021)
  • Table 76. Beta Thalassemia Testing Sales Prenatal Testing {Prenatal Genetic Testing and Chronic Villus Testing} , by Region Units (2016-2021)
  • Table 77. Beta Thalassemia Testing Sales Preimplantation Genetic Diagnosis , by Region Units (2016-2021)
  • Table 78. South America Beta Thalassemia Testing Sales, by Country Units (2016-2021)
  • Table 79. South America Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 80. South America Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 81. Brazil Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 82. Brazil Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 83. Argentina Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 84. Argentina Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 85. Rest of South America Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 86. Rest of South America Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 87. Asia Pacific Beta Thalassemia Testing Sales, by Country Units (2016-2021)
  • Table 88. Asia Pacific Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 89. Asia Pacific Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 90. China Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 91. China Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 92. Japan Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 93. Japan Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 94. India Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 95. India Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 96. South Korea Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 97. South Korea Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 98. Taiwan Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 99. Taiwan Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 100. Australia Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 101. Australia Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 102. Rest of Asia-Pacific Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 103. Rest of Asia-Pacific Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 104. Europe Beta Thalassemia Testing Sales, by Country Units (2016-2021)
  • Table 105. Europe Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 106. Europe Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 107. Germany Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 108. Germany Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 109. France Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 110. France Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 111. Italy Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 112. Italy Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 113. United Kingdom Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 114. United Kingdom Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 115. Netherlands Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 116. Netherlands Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 117. Rest of Europe Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 118. Rest of Europe Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 119. MEA Beta Thalassemia Testing Sales, by Country Units (2016-2021)
  • Table 120. MEA Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 121. MEA Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 122. Middle East Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 123. Middle East Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 124. Africa Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 125. Africa Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 126. North America Beta Thalassemia Testing Sales, by Country Units (2016-2021)
  • Table 127. North America Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 128. North America Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 129. United States Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 130. United States Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 131. Canada Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 132. Canada Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 133. Mexico Beta Thalassemia Testing Sales, by Application Units (2016-2021)
  • Table 134. Mexico Beta Thalassemia Testing Sales, by Technology Units (2016-2021)
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Beta Thalassemia Testing: by Application(USD Million)
  • Table 146. Beta Thalassemia Testing Hospitals , by Region USD Million (2022-2027)
  • Table 147. Beta Thalassemia Testing Biotechnological Laboratories , by Region USD Million (2022-2027)
  • Table 148. Beta Thalassemia Testing Diagnostic Laboratories , by Region USD Million (2022-2027)
  • Table 149. Beta Thalassemia Testing Educational Research Institutes , by Region USD Million (2022-2027)
  • Table 150. Beta Thalassemia Testing Pharmaceutical Industries , by Region USD Million (2022-2027)
  • Table 151. Beta Thalassemia Testing: by Technology(USD Million)
  • Table 152. Beta Thalassemia Testing Perinatal Testing {Complete Blood Count and DNA Testing} , by Region USD Million (2022-2027)
  • Table 153. Beta Thalassemia Testing Prenatal Testing {Prenatal Genetic Testing and Chronic Villus Testing} , by Region USD Million (2022-2027)
  • Table 154. Beta Thalassemia Testing Preimplantation Genetic Diagnosis , by Region USD Million (2022-2027)
  • Table 155. South America Beta Thalassemia Testing, by Country USD Million (2022-2027)
  • Table 156. South America Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 157. South America Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 158. Brazil Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 159. Brazil Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 160. Argentina Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 161. Argentina Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 162. Rest of South America Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 163. Rest of South America Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 164. Asia Pacific Beta Thalassemia Testing, by Country USD Million (2022-2027)
  • Table 165. Asia Pacific Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 166. Asia Pacific Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 167. China Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 168. China Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 169. Japan Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 170. Japan Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 171. India Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 172. India Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 173. South Korea Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 174. South Korea Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 175. Taiwan Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 176. Taiwan Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 177. Australia Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 178. Australia Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 179. Rest of Asia-Pacific Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 180. Rest of Asia-Pacific Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 181. Europe Beta Thalassemia Testing, by Country USD Million (2022-2027)
  • Table 182. Europe Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 183. Europe Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 184. Germany Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 185. Germany Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 186. France Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 187. France Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 188. Italy Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 189. Italy Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 190. United Kingdom Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 191. United Kingdom Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 192. Netherlands Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 193. Netherlands Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 194. Rest of Europe Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 195. Rest of Europe Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 196. MEA Beta Thalassemia Testing, by Country USD Million (2022-2027)
  • Table 197. MEA Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 198. MEA Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 199. Middle East Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 200. Middle East Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 201. Africa Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 202. Africa Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 203. North America Beta Thalassemia Testing, by Country USD Million (2022-2027)
  • Table 204. North America Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 205. North America Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 206. United States Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 207. United States Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 208. Canada Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 209. Canada Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 210. Mexico Beta Thalassemia Testing, by Application USD Million (2022-2027)
  • Table 211. Mexico Beta Thalassemia Testing, by Technology USD Million (2022-2027)
  • Table 212. Beta Thalassemia Testing Sales: by Application(Units)
  • Table 213. Beta Thalassemia Testing Sales Hospitals , by Region Units (2022-2027)
  • Table 214. Beta Thalassemia Testing Sales Biotechnological Laboratories , by Region Units (2022-2027)
  • Table 215. Beta Thalassemia Testing Sales Diagnostic Laboratories , by Region Units (2022-2027)
  • Table 216. Beta Thalassemia Testing Sales Educational Research Institutes , by Region Units (2022-2027)
  • Table 217. Beta Thalassemia Testing Sales Pharmaceutical Industries , by Region Units (2022-2027)
  • Table 218. Beta Thalassemia Testing Sales: by Technology(Units)
  • Table 219. Beta Thalassemia Testing Sales Perinatal Testing {Complete Blood Count and DNA Testing} , by Region Units (2022-2027)
  • Table 220. Beta Thalassemia Testing Sales Prenatal Testing {Prenatal Genetic Testing and Chronic Villus Testing} , by Region Units (2022-2027)
  • Table 221. Beta Thalassemia Testing Sales Preimplantation Genetic Diagnosis , by Region Units (2022-2027)
  • Table 222. South America Beta Thalassemia Testing Sales, by Country Units (2022-2027)
  • Table 223. South America Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 224. South America Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 225. Brazil Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 226. Brazil Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 227. Argentina Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 228. Argentina Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 229. Rest of South America Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 230. Rest of South America Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 231. Asia Pacific Beta Thalassemia Testing Sales, by Country Units (2022-2027)
  • Table 232. Asia Pacific Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 233. Asia Pacific Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 234. China Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 235. China Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 236. Japan Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 237. Japan Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 238. India Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 239. India Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 240. South Korea Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 241. South Korea Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 242. Taiwan Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 243. Taiwan Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 244. Australia Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 245. Australia Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 246. Rest of Asia-Pacific Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 247. Rest of Asia-Pacific Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 248. Europe Beta Thalassemia Testing Sales, by Country Units (2022-2027)
  • Table 249. Europe Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 250. Europe Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 251. Germany Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 252. Germany Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 253. France Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 254. France Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 255. Italy Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 256. Italy Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 257. United Kingdom Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 258. United Kingdom Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 259. Netherlands Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 260. Netherlands Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 261. Rest of Europe Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 262. Rest of Europe Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 263. MEA Beta Thalassemia Testing Sales, by Country Units (2022-2027)
  • Table 264. MEA Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 265. MEA Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 266. Middle East Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 267. Middle East Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 268. Africa Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 269. Africa Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 270. North America Beta Thalassemia Testing Sales, by Country Units (2022-2027)
  • Table 271. North America Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 272. North America Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 273. United States Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 274. United States Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 275. Canada Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 276. Canada Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 277. Mexico Beta Thalassemia Testing Sales, by Application Units (2022-2027)
  • Table 278. Mexico Beta Thalassemia Testing Sales, by Technology Units (2022-2027)
  • Table 279. Research Programs/Design for This Report
  • Table 280. Key Data Information from Secondary Sources
  • Table 281. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Beta Thalassemia Testing: by Application USD Million (2016-2021)
  • Figure 5. Global Beta Thalassemia Testing: by Technology USD Million (2016-2021)
  • Figure 6. South America Beta Thalassemia Testing Share (%), by Country
  • Figure 7. Asia Pacific Beta Thalassemia Testing Share (%), by Country
  • Figure 8. Europe Beta Thalassemia Testing Share (%), by Country
  • Figure 9. MEA Beta Thalassemia Testing Share (%), by Country
  • Figure 10. North America Beta Thalassemia Testing Share (%), by Country
  • Figure 11. Global Beta Thalassemia Testing: by Application Units (2016-2021)
  • Figure 12. Global Beta Thalassemia Testing: by Technology Units (2016-2021)
  • Figure 13. South America Beta Thalassemia Testing Share (%), by Country
  • Figure 14. Asia Pacific Beta Thalassemia Testing Share (%), by Country
  • Figure 15. Europe Beta Thalassemia Testing Share (%), by Country
  • Figure 16. MEA Beta Thalassemia Testing Share (%), by Country
  • Figure 17. North America Beta Thalassemia Testing Share (%), by Country
  • Figure 18. Global Beta Thalassemia Testing share by Players 2021 (%)
  • Figure 19. Global Beta Thalassemia Testing share by Players (Top 3) 2021(%)
  • Figure 20. Global Beta Thalassemia Testing share by Players (Top 5) 2021(%)
  • Figure 21. BCG Matrix for key Companies
  • Figure 22. Genorama Ltd. (Estonia) Revenue, Net Income and Gross profit
  • Figure 23. Genorama Ltd. (Estonia) Revenue: by Geography 2021
  • Figure 24. HiMedia Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 25. HiMedia Laboratories (India) Revenue: by Geography 2021
  • Figure 26. DiagCor Bioscience Inc Ltd (China) Revenue, Net Income and Gross profit
  • Figure 27. DiagCor Bioscience Inc Ltd (China) Revenue: by Geography 2021
  • Figure 28. Tosoh Bioscience, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Tosoh Bioscience, Inc. (United States) Revenue: by Geography 2021
  • Figure 30. Goffin Molecular Technologies B.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 31. Goffin Molecular Technologies B.V. (Netherlands) Revenue: by Geography 2021
  • Figure 32. Devyser (Sweden) Revenue, Net Income and Gross profit
  • Figure 33. Devyser (Sweden) Revenue: by Geography 2021
  • Figure 34. Hybribio (China) Revenue, Net Income and Gross profit
  • Figure 35. Hybribio (China) Revenue: by Geography 2021
  • Figure 36. Bio-Active Co., Ltd. (Thailand) Revenue, Net Income and Gross profit
  • Figure 37. Bio-Active Co., Ltd. (Thailand) Revenue: by Geography 2021
  • Figure 38. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 39. Bio-Rad Laboratories (United States) Revenue: by Geography 2021
  • Figure 40. Genomed Biotech (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 41. Genomed Biotech (United Kingdom) Revenue: by Geography 2021
  • Figure 42. Global Beta Thalassemia Testing: by Application USD Million (2022-2027)
  • Figure 43. Global Beta Thalassemia Testing: by Technology USD Million (2022-2027)
  • Figure 44. South America Beta Thalassemia Testing Share (%), by Country
  • Figure 45. Asia Pacific Beta Thalassemia Testing Share (%), by Country
  • Figure 46. Europe Beta Thalassemia Testing Share (%), by Country
  • Figure 47. MEA Beta Thalassemia Testing Share (%), by Country
  • Figure 48. North America Beta Thalassemia Testing Share (%), by Country
  • Figure 49. Global Beta Thalassemia Testing: by Application Units (2022-2027)
  • Figure 50. Global Beta Thalassemia Testing: by Technology Units (2022-2027)
  • Figure 51. South America Beta Thalassemia Testing Share (%), by Country
  • Figure 52. Asia Pacific Beta Thalassemia Testing Share (%), by Country
  • Figure 53. Europe Beta Thalassemia Testing Share (%), by Country
  • Figure 54. MEA Beta Thalassemia Testing Share (%), by Country
  • Figure 55. North America Beta Thalassemia Testing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Genorama Ltd. (Estonia)
  • HiMedia Laboratories (India)
  • DiagCor Bioscience Inc Ltd (China)
  • Tosoh Bioscience, Inc. (United States)
  • Goffin Molecular Technologies B.V. (Netherlands)
  • Devyser (Sweden)
  • Hybribio (China)
  • Bio-Active Co., Ltd. (Thailand)
  • Bio-Rad Laboratories (United States)
  • Genomed Biotech (United Kingdom)
Select User Access Type

Key Highlights of Report


May 2022 167 Pages 77 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Growing Number of Patients Suffering From Beta Thalassemia " is seen as one of major growth factors of Beta Thalassemia Testing Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
United States and Chinese will lead Beta Thalassemia Testing Market in coming years.

Know More About Global Beta Thalassemia Testing Market Report?